کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1968351 | 1538763 | 2006 | 5 صفحه PDF | دانلود رایگان |

BackgroundWe investigated whether the CYP2C9 genotypes would affect lornoxicam metabolism in healthy volunteers.MethodsTwelve healthy volunteers who had been genotyped for CYP2C9 gene were selected to participate in our study. After 8 mg lornoxicam was taken, blood samples were drawn from 0 to 36 h. The plasma concentrations of lornoxicam and 5′-hydroxylornoxicam were determined by HPLC method. 5′-hydroxylornoxicam was purified from rabbits'urine by semi-preparative HPLC.ResultsLornoxicam and 5′-hydroxylornoxicam both exhibit CYP2C9 genotype-dependent pharmacokinetic profiles. The area under the plasma concentration–time curve (AUC) of lornoxicam increased by 60 ± 9.78% (P < 0.05) and the AUC of 5′-hydroxylornoxicam decreased by 65 ± 11.75% (p < 0.001) in heterozygous CYP2C9*1/*3 subjects (n = 6) compared with CYP2C9*1/*1 group (n = 6). t1 / 2 value of lornoxicam and 5′-hydroxylornoxicam prolonged by 39 ± 8.35% and curtailed by 59 ± 6.83% respectively in CYP2C9*1/*3 subjects. But no significant differences in Tmax of lornoxicam and 5′-hydroxylornoxicam were observed between these 2 genotypes. In addition, for the first time we exploit the purification method for 5′-hydroxylornoxicam from rabbits' urine.ConclusionThe CYP2C9*3 allele significantly affected the metabolism of lornoxicam. The pharmacokinetic parameters of both lornoxicam and 5′-hydroxylornoxicam were significantly different between these 2 genotypes.
Journal: Clinica Chimica Acta - Volume 364, Issues 1–2, February 2006, Pages 287–291